- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00459043
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
1 juillet 2013 mis à jour par: Robert I. Haddad, MD, Dana-Farber Cancer Institute
Randomized Phase II Study of Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
In this research study, the researchers are comparing the combination of docetaxel and Zactima with docetaxel alone to see if the combination of the two drugs will be more effective than docetaxel alone.
Zactima blocks the actions of three substances in the body: 1)vascular endothelial growth factor reception (VEGFR); 2)epidermal growth factor receptor (EGFR); and 3) rearranged during transfection (RET).
VEGFR stimulates the growth of new blood vessels.
When certain proteins bind to the VEGF receptor, a process begins to occur which allows new blood vessels to be made that provide blood to the cancer cells.
Zactima is thought to block these proteins from binding to the VEGF receptor, which would then block the process that creates new blood vessels.
EGFR controls how quickly cells grow and multiply.
RET is thought to have a particularly significant role in the development and growth of squamous cell tumors.
The actions of Zactima are very different from the way standard chemotherapy drugs work.
Researchers believe that Zactima might have different side effects from other cancer treatments so another one of the purposes of this study is to assess the side effects caused by the drug.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
- Participants will be "randomized" into one of the following study groups: Docetaxel or Docetaxel with Zactima. Randomization means that participants will be put into a group by chance.
- The Docetaxel group will receive docetaxel on the first day of every treatment cycle, which lasts for 3 weeks. Even though treatment will occur once every three weeks, participants will return to the clinic on a weekly basis for the first two cycles. After the first two cycles, they will only have to return to the clinic at the start of each cycle.
- The combination Docetaxel and Zactima group will also receive docetaxel once every three weeks. In addition to the docetaxel, they will also take a Zactima pill orally every morning. They will also have to return to the clinic on a weekly basis just as those in the docetaxel only group.
- The following tests and procedures will be performed during each cycle of treatment, regardless of which group the participant is randomized into. These are considered standard of care for treating patients with chemotherapy for recurrent head and neck cancer: physical exams; blood tests; urine test; nasopharyngoscopy; repeat imaging of the tumor (x-ray, CT, MRI or PET); photographs of the tumor. In addition to the tests mentioned above, the Zactima group will have EKGs performed 3 times on the first day of treatment, once at week 2, then at the beginning of cycles 2 and 3, and then every 6 weeks.
- Participants will continue on the study as long as they are receiving benefit and are not experiencing any unmanageable side effects.
Type d'étude
Interventionnel
Inscription (Réel)
30
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Illinois
-
Maywood, Illinois, États-Unis, 60153
- Loyola University Medical Center/Cardinal Bernadin Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Histologically/cytologically documented SCCHN, excluding nasopharyngeal carcinoma. Squamous cell carcinomas of unknown primary are allowed. Primary salivary gland tumors and tumor of the nasal cavity and paranasal sinuses are not included.
- 18 years of age or older.
- Evaluable or uni-dimensionally measurable local-regional and/or metastatic disease that is not amendable to primary surgical resection or radiotherapy.
- Life expectancy of at least 3 months.
- ECOG performance status of 0-2.
- Negative pregnancy test for women of childbearing potential.
- Adequate bone marrow function.
Exclusion Criteria:
- Evidence of sever or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the trial.
- Clinically significant cardiac event such as myocardial infarction, NYHA classification of heart disease grade II or higher within 3 months of study entry, or presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia.
- History of arrhythmia which is symptomatic or requires treatment or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded.
- Previous history of QTc prolongation as a result from other medication that required discontinuation of that medication.
- Congenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age.
- Presence of left bundle branch block.
- QTc with Bazett's correction that is unmeasurable or > 480 msec on screening ECG.
- Any concomitant medication that may cause QTC prolongation, induce Torsades de Pointes or induce CYP3A4 function.
- Hypertension not controlled by medical therapy.
- Currently active diarrhea that may affect the ability of the patient to absorb Zactima.
- Pregnant or breast-feeding women.
- Previous or concurrent malignancies of other histologies within the last 5 years, with the exception of cervical carcinoma in-situ and adequately treated basal cell or squamous cell carcinoma of the skin.
- Receipt of any investigational agents within 30 days prior to commencing study treatment.
- Prior treatment with docetaxel.
- Last dose of prior chemotherapy discontinued less than 3 weeks before start of study therapy.
- Last dose of radiation therapy within the last 4 weeks before the start of study therapy, except palliative radiotherapy.
- Major surgery within 4 weeks, or incompletely healed surgical incision.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: 1
Docetaxel Alone
|
Given on the first day of every treatment cycle (every 3 weeks)
|
|
Comparateur actif: 2
Docetaxel with ZD6474
|
Given on the first day of every treatment cycle (every 3 weeks)
Taken orally once every morning
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Partial Response Rate in Both Groups of Patients.
Délai: 3 years
|
Objective tumor response was evaluated radiogically using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.
For target lesions: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) >= 30% decrease in the sum of the longest diamter of target lesions; Overall Response (OR) = CR+PR
|
3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
La survie globale
Délai: 3 années
|
3 années
|
|
|
Progression Free Survival
Délai: 3 years
|
Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sumof the longest diameter of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions
|
3 years
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 mars 2007
Achèvement primaire (Réel)
1 mars 2010
Achèvement de l'étude (Réel)
1 février 2012
Dates d'inscription aux études
Première soumission
10 avril 2007
Première soumission répondant aux critères de contrôle qualité
10 avril 2007
Première publication (Estimation)
11 avril 2007
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
3 juillet 2013
Dernière mise à jour soumise répondant aux critères de contrôle qualité
1 juillet 2013
Dernière vérification
1 juillet 2013
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs par site
- Tumeurs, glandulaires et épithéliales
- Tumeurs de la tête et du cou
- Tumeurs à cellules squameuses
- Carcinome
- Carcinome épidermoïde
- Carcinome épidermoïde de la tête et du cou
- Mécanismes moléculaires de l'action pharmacologique
- Agents antinéoplasiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Docétaxel
Autres numéros d'identification d'étude
- 06-283
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .